Semaglutide Just Outperformed Every FDA-Approved Alcohol Medication. It’s Still Not Approved For That.

Just 0.9% of Americans with alcohol use disorder receive medication for it, per NIAAA’s most recent national survey data — and part of the reason is that the three FDA-approved options — naltrexone, acamprosate, disulfiram — have real limits doctors already know well. Now there’s a fourth candidate nobody built for this job.

The best new alcohol medicine in a decade is a weight-loss drug that was never designed to treat drinking at all.

An 8-week randomized trial out of the University of Colorado, reported by Healio, gave 24 adults with alcohol use disorder low-dose oral semaglutide — the same drug family sold as Ozempic and Wegovy — and compared them to 26 on placebo. The treatment group cut heavy drinking days and drinks-per-drinking-day significantly more than placebo. Interestingly, semaglutide didn’t blunt craving in a lab test where researchers put a real drink in front of participants and measured their reaction — but it did reduce how much people reported craving alcohol day to day, out in their actual lives. “In our study, semaglutide had larger effects on consumption than these existing [FDA-approved] medications,” said Joseph Schacht, PhD, the study’s lead researcher.

That’s not a small claim from a small trial. It’s now backed by a bigger one: a Lancet-published trial of 108 participants with both alcohol use disorder and obesity tested once-weekly injectable semaglutide against placebo, on top of standard cognitive behavioral therapy, over 26 weeks — and found the same direction of effect at a larger scale.

Here’s the catch, and it’s the whole story: none of this makes semaglutide an approved alcohol use disorder treatment. It’s prescribed off-label for drinking, if it’s prescribed for that at all, and insurers are not required to cover it for a diagnosis it isn’t approved to treat. Millions of Americans are already taking a GLP-1 drug for weight loss or diabetes and may be experiencing exactly this effect on their drinking without their prescriber ever having discussed it, screened for it, or documented it. Schacht is right that “larger and longer trials of this class of medications are needed.” He’s also right that they “may ultimately lead to a paradigm shift in alcohol use disorder pharmacotherapy” — but paradigm shifts take years, and the treatment gap is now.